Drug Trial Radar · NCT07616206
Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) Systems
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Sep 29, 2026
Primary completion
Jun 2027
Study completion Jun 2027
Sponsor
- Lead sponsor
- vTv TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jun 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TTP399-206 is a Phase 2a multicenter double blind cross over randomized study of cadisegliatin in participants with T1D using hybrid closed loop systems to manage their diabetes. Participants using a hybrid closed loop insulin pump to manage their diabetes will be randomized to either receive blinded cadisegliatin 800 mg QD as an adjunctive therapy to their insulin treatment or placebo QD along with their insulin treatment. The trial begins with a screening period of up to 2 weeks, followed by a device training and insulin adjustment period of 1-2 weeks leading into the first double-blind treatment period of 6 weeks. There will then be a washout period of 2 weeks followed by the second double-blind treatment period of 6 weeks where the participants will cross-over to the treatment that they did not receive in the first treatment period.
Conditions
- Type 1 Diabetes (T1D)
Interventions
Cadisegliatin 800 mg QDDrug
Cadisegliatin is an orally bioavailable small-molecule glucokinase activator, adjunctive therapy to insulin
PlaceboDrug
Placebo (insulin alone)
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the change in Time in Range (TIR)Time frame: last 2 weeks of the two 6-week treatment periods
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Paradigm Clinical Research -Modesto
Modesto, California · Recruiting
Paradigm Clinical Research Centers, LLC
San Diego, California · Recruiting
Barbara Davis Center for Diabetes
Aurora, Colorado · Recruiting
Atlanta Diabetes Associates
Atlanta, Georgia · Recruiting
UNC Eastowne Medical Office Building
Chapel Hill, North Carolina · Recruiting
Texas Diabetes & Endocrinology, P.A.
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.